STATE AND DEVELOPMENT TRENDS OF THE PHARMACEUTICAL INDUSTRY Litiahina Mariia DIPLOMA PROJECT.
-
Upload
damian-waters -
Category
Documents
-
view
215 -
download
1
Transcript of STATE AND DEVELOPMENT TRENDS OF THE PHARMACEUTICAL INDUSTRY Litiahina Mariia DIPLOMA PROJECT.
STATE AND DEVELOPMENT TRENDS OF THE PHARMACEUTICAL INDUSTRY
Litiahina Mariia
DIPLOMA PROJECT
• The topicality of the problem is connected with the fact that the pharmaceutical market today is one of the most promising and fastest growing markets in the economy of Ukraine.
• The Purpose of the diploma project is to investigate the state and development trends of the pharmaceuticals industry and compose recommendations to improve the competitive capacity of enterprises of the pharmaceutical market of Ukraine.
Medicines consumption in Ukraine, bn packages
Table 1
Medicines consumption in Ukraine, USD bn
Table 2
Export of pharmaceutical products from Ukrainaine, USD m
2009 2010 2011 2012 2013 20140
50
100
150
200
250
92
130
151 150
199 195
Table 3
Export of pharmaceutical products
by countries, %
8%
12%
Figure 1
Distributors segment in Ukraine
№ Company Market share %
1 BaDM 28%
2 Optima-Pharm 26%
3 Alba Ukraine 20%
4 Fra-M 7%
5 Venta 7%
Table 4
Main pharmacy chains
№ Company Market share %
1 Med-Service Group 2,95%
2 Farmaciya (Kharkiv) 2,26%
3 Ukrainian Pharmacy Holding 1,89%
4 Arnika 1,88%
5 Farmastor 1,75%
6 Farmaciya (Kyiv) 1,55%
7 Bazhayemo Zdorovya 1,53%
8 Apteka Nyzkyh Tsin 1,5%
9 Falbi 1,46%
10 Titan 1.42%
Table 5
Pharmaceutical Enterprise “Jelfa” SA
A Pharmaceutical Enterprise Jelfa SA – one of the biggest Polish pharmaceutical companies.
1945 – created Pharmaceutical Enterprise Jelfa 2011 – the Company owner has been an international corporation Valeant Pharmaceuticals International (Canada)
Subdivision Pharmaceutical market
Figure 2
Main competitors of “Jelfa”
Sort by €, MonthMarket Org Sales, k€ GR% MS%Total 1 627 14,2% 100,0%01. Merck & Co (USA) 409 13,1% 25,2%02. Stada-Nizhpharm (Germany-Russia) 174 17,1% 10,7%03. Arterium Corporation OJSC (Ukraine, Kiev) 168 6,1% 10,3%04. Jelfa (Poland) 147 7,0% 9,0%05. Astellas Pharma Europe (Netherlands) 135 21,1% 8,3%06. Darnitsa CJSC (Ukraine, Kiev) 107 6,6% 6,6%07. GSK (Great Britain) 106 16,7% 6,5%08. Sperco Ukraine JV LLC (Ukraine, Vinnitsa) 88 18,7% 5,4%09. Intendis (Germany) 43 0,3% 2,6%10. Gedeon Richter (Hungary) 42 4,9% 2,6%Others 208 31,3% 12,8%
Month
Table 6
Figure 3
SWOT Analysis
• the high level of demand for the company's products
• increase consumer confidence in new products
• the ability to use know-how
• rising inflation• decline in purchasing power• reduced demand for products• increasing energy tariffs
• An effective system of quality control
• the possibility of expanding the range
• established system updated products
• good reputation of the company
• A lot of competitors• lack of marketing research• rarity promotional campaigns
Conclusions and Recommendations:
• promotion of a relatively new company product – Atopra
Conclusions and Recommendations:
• to implement and master the production of dermatological shampoos and care products for problem hair and scalp
Thank you for your attention